ADVERTISEMENT
Dr Laubach Reviews Phase 2 GRIFFIN Study Results in Newly Diagnosed MM
Jacob Laubach, MD, MPP, Dana-Farber Cancer Institute, discusses new results from the Phase 2 GRIFFIN study of daratumumab as part of a quadruplet regimen in newly diagnosed multiple myeloma, presented at the ASH 2021 Annual Meeting.
Disclaimer: The views and opinions expressed are those of the author(s) and do not necessarily reflect the official policy or position of Oncology Learning Network or HMP Global, their employees, and affiliates. Any content provided by our bloggers or authors are of their opinion and are not intended to malign any religion, ethnic group, club, association, organization, company, individual, anyone, or anything.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement